A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis.

Aref Al-Kali; Ibrahim Aldoss; Carrie Strand; Bijal D. Shah; Jonathan Allen Webster; Bhavana Bhatnagar; Mojtaba Akhtari; L. Austin Doyle; Scott H. Kaufmann

A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis.

Aref Al-Kali, Ibrahim Aldoss, Carrie Strand, Bijal D. Shah, Jonathan Allen Webster, Bhavana Bhatnagar, Mojtaba Akhtari, L. Austin Doyle, Scott H. Kaufmann

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
State	Published - May 26 2019

Disciplines

Oncology
Pathology
Medicine and Health Sciences

OpenUrl availability

Full text

Cite this

@article{f30a673ff9224cda8a0168108ece11d9,

title = "A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis.",

author = "Aref Al-Kali and Ibrahim Aldoss and Carrie Strand and Shah, {Bijal D.} and Webster, {Jonathan Allen} and Bhavana Bhatnagar and Mojtaba Akhtari and Doyle, {L. Austin} and Kaufmann, {Scott H.}",

note = "e18506 Background: Sapanisertib (SAP) is an oral small molecule dual mTOR complex 1 and 2 (TORC1/2) inhibitor that showed activity in lymphoid neoplasms. It blocks a feedback loop involving mTORC2 activation when TORC1 is selectively inhibited (Yun S et al, Blood 2016).",

year = "2019",

month = may,

day = "26",

language = "American English",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis.

AU - Al-Kali, Aref

AU - Aldoss, Ibrahim

AU - Strand, Carrie

AU - Shah, Bijal D.

AU - Webster, Jonathan Allen

AU - Bhatnagar, Bhavana

AU - Akhtari, Mojtaba

AU - Doyle, L. Austin

AU - Kaufmann, Scott H.

N1 - e18506 Background: Sapanisertib (SAP) is an oral small molecule dual mTOR complex 1 and 2 (TORC1/2) inhibitor that showed activity in lymphoid neoplasms. It blocks a feedback loop involving mTORC2 activation when TORC1 is selectively inhibited (Yun S et al, Blood 2016).

PY - 2019/5/26

Y1 - 2019/5/26

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e18506

M3 - Article

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis.

Disciplines

OpenUrl availability

Other files and links

Cite this